These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26240115)

  • 21. TMEM16A contributes to angiotensin II-induced cerebral vasoconstriction via the RhoA/ROCK signaling pathway.
    Li RS; Wang Y; Chen HS; Jiang FY; Tu Q; Li WJ; Yin RX
    Mol Med Rep; 2016 Apr; 13(4):3691-9. PubMed ID: 26955761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
    Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):243-253. PubMed ID: 28608026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olmesartan medoxomil: current status of its use in monotherapy.
    Brunner HR
    Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.
    Smith RD; Yokoyama H; Averill DB; Cooke L; Brosnihan KB; Schiffrin EL; Ferrario CM
    Am J Cardiovasc Drugs; 2006; 6(5):335-42. PubMed ID: 17083268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats.
    Kobayashi N; Nakano S; Mita S; Kobayashi T; Honda T; Tsubokou Y; Matsuoka H
    J Pharmacol Exp Ther; 2002 May; 301(2):459-66. PubMed ID: 11961044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
    Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
    Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
    Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):255-263. PubMed ID: 28608025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Air pollution and cardiac remodeling: a role for RhoA/Rho-kinase.
    Ying Z; Yue P; Xu X; Zhong M; Sun Q; Mikolaj M; Wang A; Brook RD; Chen LC; Rajagopalan S
    Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1540-50. PubMed ID: 19286943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Captopril pretreatment protects the lung against severe acute pancreatitis induced injury via inhibiting angiotensin II production and suppressing Rho/ROCK pathway.
    Yu QH; Guo JF; Chen Y; Guo XR; Du YQ; Li ZS
    Kaohsiung J Med Sci; 2016 Sep; 32(9):439-45. PubMed ID: 27638402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ontogenetic changes in contribution of calcium sensitization and calcium entry to blood pressure maintenance of Wistar-Kyoto and spontaneously hypertensive rats.
    Behuliak M; Vavřínová A; Bencze M; Polgárová K; Ergang P; Kuneš J; Vaněčková I; Zicha J
    J Hypertens; 2015 Dec; 33(12):2443-54. PubMed ID: 26418671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients.
    Ichikawa S; Takayama Y
    Hypertens Res; 2001 Nov; 24(6):641-6. PubMed ID: 11768722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II activates the RhoA exchange factor Arhgef1 in humans.
    Carbone ML; Brégeon J; Devos N; Chadeuf G; Blanchard A; Azizi M; Pacaud P; Jeunemaître X; Loirand G
    Hypertension; 2015 Jun; 65(6):1273-8. PubMed ID: 25870189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).
    Igase M; Yokoyama H; Ferrario CM
    Ther Adv Cardiovasc Dis; 2011 Dec; 5(6):297-304. PubMed ID: 22089474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.
    Ferrario C
    Vasc Health Risk Manag; 2009; 5(1):301-14. PubMed ID: 19436655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
    Mallion JM; Heagerty A; Laeis P
    J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy.
    Takahashi T; Konta T; Takasaki S; Ichikawa K; Takeishi Y; Kubota I
    Clin Exp Nephrol; 2007 Sep; 11(3):202-208. PubMed ID: 17891346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does p63RhoGEF, a new key mediator of angiotensin II signalling, play a role in blood pressure regulation and cardiovascular remodelling in humans?
    Calò LA; Davis PA; Pessina AC
    J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):634-6. PubMed ID: 22147804
    [No Abstract]   [Full Text] [Related]  

  • 40. Olmesartan medoxomil: a review of its use in the management of hypertension.
    Scott LJ; McCormack PL
    Drugs; 2008; 68(9):1239-72. PubMed ID: 18547134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.